arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Phio Pharmaceuticals Corp.

PHIO
$1.01 ▲ +0.01 (+1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
94 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Phio Pharmaceuticals Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.7M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -26.8%
FCF / Share $-0.35
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

94-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-4.00M
↓ -126.3%
FCF / Share Free cash flow per share
$-0.35
↓ -0.8%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
18
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 23 years · 94 quarters